JunD通过保护细胞免受氧化应激的影响来减少瘤血管生成
Damien Gerald1, Edurne Berra, Yves M Frapart
1Unit of Gene Expression and Diseases, CNRS URA 1644, Pasteur Institute, 25 Rue du Docteur Roux, 75724 Paris, Cedex 15, France.
Cell
|September 17, 2004
概括
转录因子JunD通过减少活性氧物种 (ROS) 和限制血管形成来抑制瘤生长. 这项研究揭示了JUND在抗氧化防御和血管生成调节中的作用.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞生理学 细胞生理学
背景情况:
- 反应性氧物种 (ROS) 在癌症发展中起着至关重要的作用.
- 瘤血管生成,新血管的形成,对于瘤生长和转移至关重要.
- 转录因子调节参与细胞过程的基因表达,如氧化应激和血管生成.
研究的目的:
- 为了研究JunD在调节瘤血管生成中的作用.
- 阐明JunD影响活性氧物种 (ROS) 生产的分子机制.
- 了解JunD如何影响缺氧诱导因子 (HIF) 途径及其对血管生成的影响.
主要方法:
- 利用缺乏JunD的细胞来研究基因调节.
- 评估了JunD对与抗氧化剂防御,H2O2产生和血管生成相关的基因的影响.
- 分析了H2O2积累对FeII可用性和HIF基酶 (PHDs) 活性的影响.
- 量化的HIF-α蛋白水平和VEGF-A转录.
主要成果:
- JunD缺乏导致H2O2积累增加.
- 升高的H2O2降低了PHD活性,导致HIF-α积累.
- HIF-alpha积累增强了VEGF-A转录,促进了血管生成.
- JunD被确定为参与氧化应激和血管生成的基因的调节者.
结论:
- JunD通过限制Ras介导的ROS产量,产生抗血管原作用.
- JunD保护细胞免受氧化应激,并抑制瘤血管生成.
- 该研究揭示了一种新的机制,该机制调节PHD活性和HIF稳定性,以应对氧化和铁水平.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
08:15Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
